Clinical trials: Diabetic Oculopathy
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
HELP Therapy for Dry AMD
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related…
- Trial name
- HELPuc (NCT01840683)
- Testing
- H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- B.Braun Avitum AG
Diabetic Retinopathy, Diabetic Macular Edema
PROMINENT-Eye Ancillary Study (Protocol AD)
Despite improved glycemic and systemic control for many patients with diabetes, over the past several decades, diabetic retinopathy (DR) develops and progresses in a large proportion of patients, and visual loss from diabetic eye…
- Trial name
- NCT03345901
- Testing
- Pemafibrate
- Where
- 71 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Jaeb Center for Health Research
Glaucoma, Diabetic Retinopathy
Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Glaucoma is a blinding eye disease increasingly common in older adults, particularly in African Americans, and often diagnosed late in the disease course.
- Conditions
- Glaucoma, Diabetic Retinopathy, Refractive Errors, Cataract
- Trial name
- AL-SIGHT (NCT04328207)
- Testing
- No Financial Incentive, Financial Incentive
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Retinal Neovascularization
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
The purpose of this study is to determine the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.
- Trial name
- NCT01769183
- Testing
- Squalamine Lactate ophthalmic solution 0.2%
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Elman Retina Group
Diabetic Retinopathy
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
The main objectives of this observational study were to describe outcomes, monitoring and treatment patterns of patients with diabetic macular edema in routine clinical practice who are either treatment naïve patients or…
- Trial name
- APOLLON (NCT02924311)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 402 people
- Sponsor
- Bayer
Diabetic Macular Edema, Macular Edema
Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study
This study aims to evaluate the influence and prognostic value of systemic factors (such as the cardiovascular and metabolic status) on the treatment response to anti-VEGF therapy in macular edema due to diabetes or retinal vein…
- Conditions
- Diabetic Macular Edema, Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT03762226
- Testing
- Anti-VEGF
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Leipzig
Diabetic Macular Edema
Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
The primary objective of the study is to assess the ocular and systemic adverse events of ranibizumab (Lucentis)for DME (diabetic macular edema) following previous treatment with intravitreal bevacizumab (Avastin).
- Trial name
- REACT (NCT01982435)
- Testing
- Ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Justis Ehlers
Diabetic Retinopathy, Diabetic Macular Edema
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
Background: Diabetic macular edema (DME) is a common condition in people with diabetes. DME occurs when blood vessels in the eye leak fluid, resulting in swelling inside the back of the eye and progressive vision loss.
- Trial name
- NCT01168258
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Retinopathy (DR)
To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy
N-acetylcysteine (NAC) emerges as a crucial factor in mitigating oxidative stress and inhibiting vascular endothelial activation in diabetic patients, through its effect on VEGF expression as VEGF is involved in the development…
- Trial name
- NCT07634991
- Testing
- N Acetyl cysteine, 1200mg (high dose)
- Where
- 2 sites in Egypt
- Volunteers
- 76 people
- Sponsor
- Ain Shams University
Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
Diabetes mellitus is a disorder of sugar and fat metabolism which results in damage to the small blood vessels in various organs, this includes the retina - the part of the eye that processes light into a nerve impulse.
- Conditions
- Diabetic Retinopathy (DR), Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus, Diabetic Macular Edema (DME)
- Trial name
- IMLADRIS (NCT06914778)
- Testing
- Blood draw for the laboratory assessment, Urine sample
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hywel Dda Health Board
Diabetic Macular Edema
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of this study was to evaluate the efficacy and safety of brolucizumab vs. aflibercept in the treatment of patients with visual impairment due to diabetic macular edema (DME).
- Trial name
- KINGFISHER (NCT03917472)
- Testing
- Brolucizumab, Aflibercept
- Where
- 92 sites in United States, Hungary and 3 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Pivotal Trial to Assess the Clinical Performance of Ophthal-360 for the Detection of Diabetic Retinopathy
Multicenter, prospective, study to assess the performance of the Ophthal-360 platform in the diagnosis of more-than-mild Diabetic Retinopathy (mtmDR) in diabetic patients with no previous diagnosis of DR.
- Trial name
- NCT05806957
- Testing
- Fundus Photography
- Volunteers
- 500 people
- Sponsor
- Ophthalytics, Inc.
Diabetes Mellitus, Diabetic Retinopathy
Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy
The purpose of this study is to evaluate the combined effects of diabetes self-management education (DSME) and nutritional supplementation on visual function and retinopathy incidence \& progression in patients with type 1…
- Trial name
- NCT04120077
- Testing
- EyePromise DVS, EyePromise DVS plus EyePromise EZTears
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- ZeaVision, LLC
Diabetes Mellitus, Macular Edema
Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema
A Single Arm, Single Dose Study to Evaluate the Effect of intravitreal dexamethasone implant (Ozurdex®) on hard exudates of diabetic macular edema.
- Conditions
- Diabetes Mellitus, Macular Edema, Retinal Exudates and Deposits
- Trial name
- NCT02399657
- Testing
- Intravitreal dexamethasone 0.7mg implant
- Where
- 8 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Inje University
Macular Edema
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
The Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator is used to deliver an implant with medicine to the eye. AbbVie is updating the DEX PS DDS Applicator.
- Trial name
- NCT04976777
- Testing
- Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbbVie
Diabetic Retinopathy (DR), Diabete Mellitus
Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus
The objective of this study is to investigate the efficacy of implementing the AI-SaMD(VUNO Med®-Fundus AI™) alongside routine clinical practice for the detection of diabetic retinopathy.
- Conditions
- Diabetic Retinopathy (DR), Diabete Mellitus, Fundus Photography
- Trial name
- SAFE-DM (NCT07378956)
- Testing
- VUNO Med®-Fundus AI™
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- VUNO Inc.
Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
The goal of this clinical trial is to learn about the safety of the investigational medicinal product ANXV. It will also learn about how ANXV works to treat non-proliferative diabetic retinopathy and retinal vein occlusion in…
- Trial name
- NEXUS (NCT07259928)
- Testing
- ANXV
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Annexin Pharmaceuticals AB
Diabetic Macular Edema, Neovascular (Wet) Age-Related Macular Degeneration
Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates
The purpose of this research study is to test whether a personalised care approach improves adherence compared to standard care.
- Conditions
- Diabetic Macular Edema, Neovascular (Wet) Age-Related Macular Degeneration, Intravitreal Injection
- Trial name
- ADHERE (NCT07567898)
- Testing
- multidisciplinary protocolized intervention (MPI), Routine medical care & monitoring
- Volunteers
- 200 people
- Sponsor
- Singapore Eye Research Institute
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
- Trial name
- AMARONE (NCT05919693)
- Testing
- EYE103
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Diabetic Macular Edema, Visual Impairment
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
- Trial name
- REFINE (NCT02259088)
- Testing
- Ranibizumab (RFB002), Laser
- Where
- 28 sites in China
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals